Robert J. Motzer, MD

Articles

Renal Cell Carcinoma: Future Directions in Care

April 22nd 2022

Looking toward the future management of renal cell carcinoma, experts consider treatment strategies for bone metastasis, brain metastasis, and VHL disease.

Non–Clear Cell RCC: Clinical Rationale Behind Therapy

April 22nd 2022

A brief review of the clinical rationale behind therapeutic regimens used for patients with non-clear cell carcinoma.

Patient Profile 4: Non–Clear Cell RCC Treated With Cabozantinib-Nivolumab

April 15th 2022

Experts review a clinical scenario of non–clear cell renal cell carcinoma, wherein the patient is managed with cabozantinib-nivolumab.

Clear Cell RCC: Testing Recommendations and Familial Risk

April 15th 2022

A brief discussion on the genetic risk tied to clear cell renal cell carcinoma and how that may inform familial risk and testing.

Adjuvant and Neoadjuvant Therapies Under Evaluation for Renal Cell Carcinoma

April 8th 2022

Expert perspectives on the possible roles of neoadjuvant nivolumab and adjuvant sunitinib for patients with renal cell carcinoma.

Patient Profile 3: RCC Treated With Adjuvant Pembrolizumab

April 8th 2022

A clinical scenario of renal cell carcinoma treated with surgery and adjuvant pembrolizumab is reviewed by a panel of experts.

Lenvatinib/Pembrolizumab in RCC: Dosing and Adverse Event Management

April 1st 2022

Expert perspectives on lenvatinib/pembrolizumab combination therapy in renal cell carcinoma, including appropriate dosing and adverse event management.

Risk Stratification and Factors in Selecting Therapy in RCC

April 1st 2022

Shared insight on the patient and disease factors that inform the selection of therapy for favorable-risk renal cell carcinoma.

Patient Profile 2: Favorable-Risk RCC Treated With Lenvatinib-Pembrolizumab

March 25th 2022

A second clinical scenario focusing on favorable-risk renal cell carcinoma managed with lenvatinib-pembrolizumab therapy.

Triplet Therapy Approaches for Intermediate/Poor Risk RCC

March 25th 2022

A brief discussion on triplet therapy being investigated in patients with intermediate- and poor-risk renal cell carcinoma.

I/O–I/O Therapy in Intermediate/Poor Risk RCC: Toxicity and Duration of Response

March 18th 2022

Focusing on immunotherapy in the setting of intermediate- and poor-risk renal cell carcinoma, panelists review toxicity management and duration of response.

Patient Profile 1: Intermediate/Poor Risk RCC Treated With Ipilimumab-Nivolumab

March 18th 2022

Experts review a clinical scenario of intermediate- and poor-risk renal cell carcinoma that is managed with ipilimumab-nivolumab and nivolumab maintenance.

Dr. Motzer on the Efficacy of Cabozantinib in RCC

March 18th 2021

Robert J. Motzer, MD, discusses the efficacy of cabozantinib in patients with renal cell carcinoma.

Dr. Motzer on the TIVO-1 Trial With Tivozanib in Advanced RCC

September 15th 2020

Robert J. Motzer, MD, discusses the phase 3 TIVO-1 trial comparing tivozanib with sorafenib in patients with advanced renal cell carcinoma.

Dr. Motzer on the TIVO-3 Trial Examining Tivozanib in Advanced RCC

September 2nd 2020

Robert J. Motzer, MD, discusses the results of the phase 3 TIVO-3 trial with tivozanib versus sorafenib in patients with advanced renal cell carcinoma.

Dr. Motzer on First-Line Treatment of Metastatic RCC

November 7th 2019

Robert J. Motzer, MD, discusses the first-line treatment landscape of metastatic clear cell renal cell carcinoma.

Dr. Motzer on Nivolumab/Ipilimumab Activity in RCC

February 3rd 2017

Robert J. Motzer, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, 2016 Giant of Cancer Care in Genitourinary Cancer, discusses the data seen thus far with nivolumab plus ipilimumab in the treatment of patients with renal cell carcinoma.

Dr. Motzer on the Milestone of Immunotherapy in RCC

January 27th 2017

Robert J. Motzer, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, 2016 Giant of Cancer Care in Genitourinary Cancer, discusses the explosion of immunotherapy in the landscape of renal cell carcinoma (RCC).

Dr. Motzer on Nivolumab Versus Everolimus in Renal Call Carcinoma

January 18th 2017

Robert J. Motzer, MD, attending physician, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, and professor of Medicine, Weill Medical College, Cornell University, discusses the FDA approval of nivolumab (Opdivo) versus everolimus (Afinitor) for patients with advanced renal cell carcinoma (RCC).

Dr. Motzer on a Phase II Trial of Nivolumab for mRCC

September 30th 2014

Robert J. Motzer, MD, attending physician, Memorial Sloan Kettering Cancer Center, provides an overview of a phase II study of nivolumab for the treatment of patients with clear cell metastatic renal cell carcinoma.